[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351408-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351408-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","decoding-brain-metastasis-with-liquid-biopsy-biomarkers-and-technologies-in-egfr-mutant-nsclc","Decoding Brain Metastasis With Liquid Biopsy - Biomarkers and Technologies in EGFR-Mutant NSCLC","","Brain metastasis (BM) is a leading cause of cancer-related mortality, especially in lung cancer patients. Conventional diagnostics, including tissue biopsies, are often impractical, and clinical early detection lacks dependable biomarkers. Liquid biopsy provides a non-invasive alternative, drawing attention for BM assessment. This review details the strengths and limitations of liquid biopsy samples (including reduced early-stage sensitivity and false positives). It focuses on peripheral blood and CSF, key biomarkers such as CTCs, ctDNA, EVs, and TEPs, and detection technologies, with emphasis on EGFR-mutant NSCLC, plus emerging approaches and recommendations to improve clinical application and management.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/decoding-brain-metastasis-with-liquid-biopsy-biomarkers-and-technologies-in-egfr-mutant-nsclc/351408/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/decoding-brain-metastasis-with-liquid-biopsy-biomarkers-and-technologies-in-egfr-mutant-nsclc/351408.png","ImageObject",300,407,{"name":42,"@type":43},"Alex Sinclair","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is liquid biopsy important for brain metastasis (BM)?","Question",{"text":63,"@type":64},"Liquid biopsy is valuable because tissue biopsies are often impractical for BM diagnosis, and reliable early-detection biomarkers are currently limited. It enables non-invasive sampling from peripheral blood and cerebrospinal fluid (CSF).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What limitations of liquid biopsy are discussed?",{"text":68,"@type":64},"The review highlights low sensitivity in early-stage disease and the risk of false positives arising from non-cancer sources. These issues affect reliability in clinical practice.",{"name":70,"@type":61,"acceptedAnswer":71},"Which biomarkers and technologies are emphasized for detecting EGFR-mutant NSCLC brain metastasis?",{"text":72,"@type":64},"The review focuses on biomarkers including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), and tumor-derived platelets (TEPs). It also discusses current detection technologies and their potential clinical applications, alongside emerging methods.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351408,1790190213,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Cancer Medicine  \n|  REVIEW  OPEN ACCESS \u003Cbr>Decoding Brain Metastasis With Liquid Biopsy: Biomarkers and Technologies in EGFR-Mutant NSCLC\u003Cbr>Yuxiang Sun1,2 | Qinglin Wang1,2 | Pengcheng Zhu1,2 | Zhitong Li1,2 | Tongyan Liu1,3,4 | Rong Yin1,4,5 \u003Cbr>1Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, P.R. China | 2The Fourth Clinical College of Nanjing Medical University, Nanjing, P.R. China | 3Department of Science and Technology, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, P.R. China | 4Collaborative Innovation Center for Cancer Personalized Medicine, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Nanjing Medical University, Nanjing, P.R. China | 5Department of Thoracic Surgery, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, P.R. China\u003Cbr>Correspondence: Tongyan Liu ([liutongyan@njmu.edu.cn](liutongyan@njmu.edu.cn)) | Rong Yin ([rong_yin@njmu.edu.cn](rong_yin@njmu.edu.cn))\u003Cbr>Received: 24 July 2025 | Revised: 1 January 2026 | Accepted: 30 March 2026\u003Cbr>Keywords: brain metastasis | EGFR | liquid biopsy | NSCLC |\n| --- |\n| ABSTRACT\u003Cbr>Brain metastasis (BM) is a leading cause of cancer-related mortality, particularly in patients with lung cancer. Traditional diagnostic methods, such as tissue biopsies, are often impractical, and there are currently no reliable biomarkers for early detection in clinical practice. In this context, liquid biopsy has emerged as a valuable non-invasive diagnostic tool for cancer patients with BM. This review summarizes the advantages and current limitations (such as the low sensitivity in early-stage disease and the potential for false positives from non-cancer sources) of liquid biopsy samples, specifically focusing on peripheral blood and cerebrospinal fluid (CSF) . We discuss key biomarkers, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), and tumor-derived platelets (TEPs), and current technologies for their detection, highlighting their potential clinical applications. Additionally, we explore the role of liquid biopsy in patients with epidermal growth factor receptor-mutated (EGFR-mutant) non-small cell lung cancer (NSCLC), a group that experiences a high incidence of BM. Finally, we address emerging biomarkers and innovative detection methods, offering recommendations for enhancing the application of liquid biopsy in clinical settings. Our review aims to underscore the significance of liquid biopsy in improving the detection and management of BM. |\n|  |\n| Yuxiang Sun, Qinglin Wang, and Pengcheng Zhu contributed equally to this work. |\n| Abbreviations: AFM, atomic force microscopy; AI, artificial intelligence; BBB, blood-brain barrier; BM, brain metastasis; B-Pt-Au NPs, branched Pt Au nanospheres; CAPP-Seq, cancer personalized profiling by deep sequencing; circRNA, circular RNA; CM, classification model; CNS, central nervous system; CRP, C-reactive protein; CSF, cerebrospinal fluid; CT, computed tomography; CTCs, circulating tumor cells; ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction; EGFR-mutant, epidermal growth factor receptor-mutated; EMT, epithelial-to-mesenchymal transition; EpCAM, epithelial cell adhesion molecule; EVs, extracellular vesicles; HBMECs, human brain microvascular endothelial cells; HDS, high-depth sequencing; ISET, isolation by size of epithelial tumor cells; LM, leptomeningeal metastasis; lncRNA, long non-coding RNA; MACS, magnetic-activated cell sorting; MAF, mutant allele frequency; MBP, myelin basic protein; MET, mesenchymal epithelial transition factor; miRNA, microRNA; MRI, magnetic resonance imaging; NGS, next-generation sequencing; NSCLC, non-small cell l","cbCaiu1qnakWr3dj","https://ap.wps.com/l/cbCaiu1qnakWr3dj","pdf",2020745,"English","# Abstract\n# Background\n## Precision medicine and early diagnosis\n## Limits of tissue biopsy for BM\n## Role of liquid biopsy\n# Keywords and abbreviations","[{\"question\":\"Why is liquid biopsy important for brain metastasis (BM)?\",\"answer\":\"Liquid biopsy is valuable because tissue biopsies are often impractical for BM diagnosis, and reliable early-detection biomarkers are currently limited. It enables non-invasive sampling from peripheral blood and cerebrospinal fluid (CSF).\"},{\"question\":\"What limitations of liquid biopsy are discussed?\",\"answer\":\"The review highlights low sensitivity in early-stage disease and the risk of false positives arising from non-cancer sources. These issues affect reliability in clinical practice.\"},{\"question\":\"Which biomarkers and technologies are emphasized for detecting EGFR-mutant NSCLC brain metastasis?\",\"answer\":\"The review focuses on biomarkers including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), and tumor-derived platelets (TEPs). It also discusses current detection technologies and their potential clinical applications, alongside emerging methods.\"}]","Decoding Brain Metastasis With Liquid Biopsy - Biomarkers and Technologies in EGFR-Mutant NSCLC | PDF",1790094033,48,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0fa82e561abd7e6fe298822b5f65571b.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca76727ee1f4bc01f20444dc3d58a6df.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa0bc015c8d16e9a5fe5242d5752325f.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c6d061edbbb19271ec5b157616300a4.webp",980,1287]